A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/ 6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

作者:Kalinsky Kevin; Mundi Prabhjot S.; Chiuzan Codruta; Accordino Melissa K.; Trivedi Meghna S.; Sparano Josepha A.; Oh Sun Y.; Tiersten Amy; O'Regan Ruth; Esteva Francisco J.; Jain Sarika; Mayer Ingrid A.; Forero Andres; Vaklavas Chris; Baer Lea; Crew Katherine; Hershman Dawn L.
来源:San Antonio Breast Cancer Symposium, 2017-12-05 to 2017-12-09.